MRNA vs INSM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 31, 2026

MRNA

52.8
AI Score
VS
MRNA Wins

INSM

42.5
AI Score

Investment Advisor Scores

MRNA

53score
Recommendation
HOLD

INSM

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA INSM Winner
Revenue 534.00M 1.26B INSM
Net Income -2.13B -277.12M INSM
Net Margin -397.9% -22.1% INSM
Operating Income -2.20B -244.24M INSM
ROE -31.4% -38.2% MRNA
ROA -19.4% -12.4% INSM
Total Assets 10.96B 2.23B MRNA
Cash 1.72B 396.56M MRNA
Debt/Equity 0.09 0.75 MRNA
Current Ratio 2.29 2.86 INSM
Free Cash Flow -1.25B -363.39M INSM

Relative Price Performance (Last 90 Days)

MRNA 1M: +17.3% · 3M: +302.1% INSM 1M: +3.7% · 3M: +14.4%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (47.6% over 20 days), RSI 57

RSI (14): 57.3 · Price: $221.72

INSM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 63

RSI (14): 62.8 · Price: $112.58

Fundamentals Snapshot

Metric MRNA INSM
Market Cap — —
Forward P/E -45.3 139.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 3.0%
Gross Margin -0.7% 0.8%
Operating Margin -5.6% -0.2%
EPS -7.98 -4.10
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.